CommercialCoverageLow impact
08.01.88b, Allogeneic Processed Thymus Tissue-agdc (Rethymic®)
Independence Blue Cross·Allergy & Immunology, Oncology, Pediatrics·Pharmacy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
A new commercial policy for Allogeneic Processed Thymus Tissue-agdc (Rethymic®) has been issued under policy number 08.01.88b in the Pharmacy category. This policy will become effective June 10, 2026, establishing coverage guidelines for this specialized thymus tissue treatment.
Action Required
By June 10, 2026: Billing team should review the full policy text at the provided URL to understand coverage criteria and billing requirements for Rethymic® (Allogeneic Processed Thymus Tissue-agdc). Update billing systems and provider documentation requirements once specific billing codes and coverage criteria are identified from the complete policy.